ConductScience.org, home
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
API referenceFor AI assistants

Trial · NCT02437136

Results by group78

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 78

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST)Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab22.295% Confidence Interval 6.4 to 47.6percentage of participants
Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST)Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab9.295% Confidence Interval 3.8 to 18.1percentage of participants
Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST)Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab18.995% Confidence Interval 9.4 to 32.0percentage of participants
Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST)Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab5.495% Confidence Interval 0.7 to 18.2percentage of participants
Phase 2: Clinical Benefit Rate (CBR), as Assessed Using irRECISTPhase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab33.395% Confidence Interval 13.3 to 59.0percentage of participants
Phase 2: Clinical Benefit Rate (CBR), as Assessed Using irRECISTPhase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab14.595% Confidence Interval 7.5 to 24.4percentage of participants
Phase 2: Clinical Benefit Rate (CBR), as Assessed Using irRECISTPhase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab35.895% Confidence Interval 23.1 to 50.2percentage of participants
Phase 2: Clinical Benefit Rate (CBR), as Assessed Using irRECISTPhase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab8.195% Confidence Interval 1.7 to 21.9percentage of participants
Phase 2: CBR, as Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab22.295% Confidence Interval 6.4 to 47.6percentage of participants
Phase 2: CBR, as Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab14.595% Confidence Interval 7.5 to 24.4percentage of participants
Phase 2: CBR, as Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab30.295% Confidence Interval 18.3 to 44.3percentage of participants
Phase 2: CBR, as Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab2.795% Confidence Interval 0.1 to 14.2percentage of participants
Phase 2: Progression Free Survival (PFS), as Assessed Using irRECISTPhase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab3Participants
Phase 2: Progression Free Survival (PFS), as Assessed Using irRECISTPhase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab17Participants
Phase 2: Progression Free Survival (PFS), as Assessed Using irRECISTPhase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab20Participants
Phase 2: Progression Free Survival (PFS), as Assessed Using irRECISTPhase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab3Participants
Phase 2: PFS, as Assessed Using RECIST 1.1Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab3Participants
Phase 2: PFS, as Assessed Using RECIST 1.1Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab17Participants
Phase 2: PFS, as Assessed Using RECIST 1.1Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab17Participants
Phase 2: PFS, as Assessed Using RECIST 1.1Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab2Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02437136/results

API referenceFor AI assistants